| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer LB Saltz, JV Cox, C Blanke, LS Rosen, L Fehrenbacher, MJ Moore, ... New England Journal of Medicine 343 (13), 905-914, 2000 | 3940 | 2000 |
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2013-2019, 2008 | 3740 | 2008 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3223 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3004 | 2017 |
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor LB Saltz, NJ Meropol, PJ Loehrer Sr, MN Needle, J Kopit, RJ Mayer Journal of clinical oncology 22 (7), 1201-1208, 2004 | 2286 | 2004 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2063 | 2017 |
| MethyLight: a high-throughput assay to measure DNA methylation CA Eads, KD Danenberg, K Kawakami, LB Saltz, C Blake, D Shibata, ... Nucleic acids research 28 (8), e32-00, 2000 | 1740 | 2000 |
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma GK Abou-Alfa, L Schwartz, S Ricci, D Amadori, A Santoro, A Figer, ... Journal of clinical oncology 24 (26), 4293-4300, 2006 | 1564 | 2006 |
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry KY Chung, J Shia, NE Kemeny, M Shah, GK Schwartz, A Tse, A Hamilton, ... Journal of clinical oncology 23 (9), 1803-1810, 2005 | 1417 | 2005 |
| Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ... Journal of clinical oncology 26 (12), 2006-2012, 2008 | 1101 | 2008 |
| Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 19 (3), 329-359, 2021 | 1049 | 2021 |
| American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options LE Schnipper, NE Davidson, DS Wollins, C Tyne, DW Blayney, D Blum, ... Journal of Clinical Oncology 33 (23), 2563-2577, 2015 | 1001 | 2015 |
| Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803 JA Meyerhardt, D Heseltine, D Niedzwiecki, D Hollis, LB Saltz, RJ Mayer, ... Journal of Clinical Oncology 24 (22), 3535-3541, 2006 | 924 | 2006 |
| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 903 | 2022 |
| NCCN guidelines insights: colon cancer, version 2.2018 AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018 | 903 | 2018 |
| Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (7), 874-901, 2018 | 885 | 2018 |
| Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, L Cederquist, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 15 (3), 370-398, 2017 | 773 | 2017 |
| Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ... Journal of clinical oncology 33 (34), 4032-4038, 2015 | 742 | 2015 |
| Hepatic neuroendocrine metastases: does intervention alter outcomes? RS Chamberlain, D Canes, KT Brown, L Saltz, W Jarnagin, Y Fong, ... Journal of the American College of Surgeons 190 (4), 432-445, 2000 | 712 | 2000 |
| Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 707 | 2018 |
